-
公开(公告)号:US20230192654A1
公开(公告)日:2023-06-22
申请号:US17969479
申请日:2022-10-19
Applicant: PFIZER, INC.
Inventor: Lei Zhang , Erik Alphie LaChapelle , Christopher Ryan Butler , Natasha Mariam Kablaoui , Michael Aaron Brodney , Laura Ann McAllister , Qingyi Yang , Christopher John Helal , Damien Webb
IPC: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/107
CPC classification number: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/107
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号:US11524954B2
公开(公告)日:2022-12-13
申请号:US17040479
申请日:2019-03-25
Applicant: Pfizer Inc.
Inventor: Lei Zhang , Erik Alphie LaChapelle , Christopher Ryan Butler , Natasha Mariam Kablaoui , Michael Aaron Brodney , Laura Ann McAllister , Qingyi Yang , Christopher John Helal , Damien Webb
IPC: C07D401/14 , C07D401/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/107
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号:US10316021B2
公开(公告)日:2019-06-11
申请号:US15820679
申请日:2017-11-22
Applicant: Pfizer Inc.
Inventor: Natasha Mariam Kablaoui , Michael Eric Green , Justin Ian Montgomery , Michael Aaron Brodney , Patrick Robert Verhoest , Gregory Wayne Kauffman , Danica Antonia Rankic , Scot Richard Mente , Bruce Nelsen Rogers , Kapildev Kashmirilal Arora , Matthew Francis Dunn
IPC: C07D403/04 , C07D231/20 , C07D413/04 , C07D417/04 , A61P25/00
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
-
公开(公告)号:US20210024497A1
公开(公告)日:2021-01-28
申请号:US17040479
申请日:2019-03-25
Applicant: Pfizer Inc.
Inventor: Lei Zhang , Erik Alphie LaChapelle , Christopher Ryan Butler , Natasha Mariam Kablaoui , Michael Aaron Brodney , Laura Ann McAllister , Qingyi Yang , Christopher John Helal , Damien Webb
IPC: C07D401/14 , C07D401/12 , C07D417/14 , C07D471/04 , C07D491/107 , C07D413/14
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号:US20180148432A1
公开(公告)日:2018-05-31
申请号:US15820679
申请日:2017-11-22
Applicant: Pfizer Inc.
Inventor: Natasha Mariam Kablaoui , Michael Eric Green , Justin Ian Montgomery , Michael Aaron Brodney , Patrick Robert Verhoest , Gregory Wayne Kauffman , Danica Antonia Rankic , Scot Richard Mente , Bruce Nelsen Rogers , Kapildev Kashmirilal Arora , Matthew Francis Dunn
IPC: C07D403/04 , C07D417/04 , A61P25/00 , C07D231/20 , C07D413/04
CPC classification number: C07D403/04 , A61P25/00 , C07B2200/13 , C07D231/20 , C07D413/04 , C07D417/04
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
-
-
-
-